An overview of HER2

Seminars in Oncology

Volumn 28, Issue 6 SUPPL. 18, 2001, Pages 3-11

  Lohrisch, Caroline ^a,b   Piccart, Martine ^a,b  

^a European Organization for Research   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ETOPOSIDE; FADROZOLE; FLUOROURACIL; MEGESTROL ACETATE; MELPHALAN; MEMBRANE RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; PROTEIN TYROSINE KINASE; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

BREAST CANCER; BREAST EPITHELIUM; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CELL GROWTH; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG POTENTIATION; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0035683625     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.29713     Document Type: Review

References (51)

1. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
2. Basic biology of HER2
3. ErbB3 (HER-3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase
4. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
5. Use of the anti HER-2/neu antibody, Herceptin in the treatment of human breast cancer
6. HER2 overexpression in various tumor types
7. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
8. The HER-2 (c-erbB-2) oncogene is frequently amplified in situ carcinomas of the breast
9. Development of the anti-HER2 monoclonal antibody, Herceptin
10. HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
11. 20 Year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy
12. ERBB2 expression and the benefit from 5 versus 2 years of adjuvant tamoxifen for postmenopausal stage II breast cancer patients
13. Lack of interaction of tamoxifen use and erbB-2/HER-2/neu expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil in node-positive primary breast cancer
14. ERBB2 amplification in associated with tamoxifen resistance in steroid-receptor positive breast cancer
15. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
16. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
17. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
18. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
19. Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER-2
20. The relationship between outcome following adjuvant CMF and the presence of estrogen receptor and c-erbB2 protein in 277 women with primary breast cancer
21. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
22. Prognostic importance of c-erbB-2 expression in breast cancer
23. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive hormone receptor-negative breast cancer
24. ErbB-2 overexpression and response to chemotherapy - NSABP study
25. CMF or anthracycline-based adjuvant chemotherapy for node-positive breast cancer patients: 4 Year results of a Belgian randomised clinical trial with predictive marker analysis
26. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone
27. P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
28. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
29. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
30. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary turnout in metastatic breast cancer
31. A study of the value of p53, c-erbB2 and Bcl-2 in the prediction of response to doxorubicin and Taxol as single agents in metastatic breast cancer: A companion study to EORTC 10923
32. HER-2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
33. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53, and bcl-2
34. HER-2: A "predictive factor" ready to use in daily management of breast cancer patients?
35. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer
36. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
37. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer
38. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing breast cancer that has progressed after chemotherapy for metastatic disease
39. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER-2 monoclonal antibody Herceptin in HER-2-overexpressing metastatic breast cancer
40. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity synergistic or sequential stress, or surveillance artifact?
41. Regulation of phosphorylation of the c-erbB-2/HER-2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells
42. p185HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
43. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
44. Herceptin inhibits HER-2 cleavage in breast cancer cells
45. Anti-HER-2/neu antibody induces apoptosis in HER-2/neu overexpressing breast cancer cells independent from intact p53
46. Pharmacological/screening insights into the future of Herceptin
47. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
48. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts
49. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
50. Anti-HER-2 antibody enhances the growth inhibitory effect of antiestrogen on breast cancer cells expressing both estrogen receptors and HER-2
51. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer